Co-crystal is an attractive alternative new class of solid forms because that can be engineered to have desired
physicochemical properties. Co-crystals have gained considerable attention from the generic pharmaceutical industry after
the USFDA released its finalized guidance in the year 2018 on the regulatory classification of co-crystals. In this review,
we discussed how co-crystals can be explored as a potential alternative solid form for the development of a generic
product that meets the legal, regulatory, and bioequivalence requirements. In the contents, we discussed in detail concepts
such as the selection of coformers, various ways of making co-crystals, the strategy of characterization to discriminate
between co-crystal and salt, polymorphism in co-crystals, the aspects of intellectual property and, finally, the regulatory
aspects of co-crystals.